Searched for
PHARMA PRICE INCREASE
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
Nifty has more room to run; stay selective: AnalystsIndian stock markets are showing cautious optimism, with the Nifty eyeing the 24,300-25,000 zone amid ongoing volatility. Analysts recommen...
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27%At this point, it would be good to keep some powder dry and focus on the fundamentals of sectors, especially those where underlying changes...
Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
F&O Talk: Nifty to remain rangebound, says Sudeep Shah; picks 8 stocks for next weekIndian stock markets concluded the week with modest gains, as Sensex and Nifty erased earlier surges on monthly expiry day. Analysts observ...
Why Rakesh Jhunjhunwala bought Titan shares when everyone else was selling? Raamdeo Agrawal explainsRaamdeo Agrawal recalls Rakesh Jhunjhunwala’s exceptional ability to spot undervalued stocks and build long-term wealth, highlighting his f...
Missed the FII U-turn? 6 stocks turned multibagger after foreign investors corrected their mistakeForeign institutional investors (FIIs) reversed their selling trend in six select Indian stocks, turning them into multibaggers. Bajaj Cons...
Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
India's growth story, not AI trade reversal, will drive foreign flows: Sameer DalalIndia's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correct...
Rs 1,100 crore a day nightmare: Why FIIs are ruthlessly selling bank stocksForeign investors are aggressively selling Indian bank stocks, offloading over âı1,100 crore daily due to global economic pressures and port...
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI AayogIndia's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
Smallcap funds beat all equity mutual fund categories over 3 months. Should investors change SIP strategy?Smallcap funds have emerged as the best-performing equity mutual fund category over the last three months, delivering an average return of ...
Forget AI and EVs: Zerodhaâs Nikhil Kamath spots next big billion-dollar opportunity hidden in Indiaâs biggest problemNikhil Kamath water business idea: India's rapid growth in water-intensive sectors like agriculture, nuclear energy, pharmaceuticals, and d...
Sensex rises 254 points, Nifty closes above 24,150; IndiGo, Trent among top gainersIndian stock markets closed higher on Thursday, with Sensex and Nifty extending gains for a fifth consecutive session. Despite a hawkish US...
Kiran Mazumdar-Shaw eyes crown of worldâs top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
NBFCs and private banks better positioned than PSU banks: Aman ChowhanAman Chowhan of Abakkus Asset Manager highlights crude oil as the dominant macro risk, potentially impacting corporate earnings by 100-200 ...
Falling crude, stronger rupee could boost earnings outlook for India: Deepak ShenoyIndian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...